WESTLAKE VILLAGE, Calif, Nov. 13 /PRNewswire-FirstCall/ -- QT 5, Inc.
(OTC Bulletin Board: QTFV), manufacturer, distributor and marketers of
biomedical diagnostics and NICOWater(TM), a Homeopathic Nicotinum Formula,
today announced it has successfully recruited Donald V. Cramer, D.V.M., Ph.D.
to join the Company's Medical Advisory Board. CEO, Timothy Owens said, "This
is a great addition to an already impressive team of medical professionals.
Dr. Cramer is renowned in the immunological and biological sciences. He is
extremely talented and a powerful influence in all of the disciplines that are
vital to our diagnostic products. He is especially well versed in Biological
Threat Management and has many established relationships with the NIH
(National Institute of Health). He will play a key role in maximizing the
efficiency of our product positioning and process development. In fact, we
have already benefited from Dr. Cramer's participation and his enthusiasm
further convinces me of the potential of our products and the strength of our
strategies."
Donald V. Cramer, D.V.M., Ph.D.
Dr. Cramer brings to QT5, Inc. his background as a distinguished scientist
and consultant in biomedical sciences. He is an internationally recognized
scientist in the areas of transplantation biology, immunology and pathology.
Dr. Cramer has held academic appointments as Professor of Research, Keck
School of Medicine, University of Southern California, and Associate Professor
of Pathology with tenure at the University of Pittsburgh School of Medicine.
Dr. Cramer received his D.V.M. degree from the University of California at
Davis in 1966, a Ph.D in Experimental pathology from Harvard University,
Cambridge, Massachusetts, in 1978. Dr. Cramer is a Diplomat of the American
College of Veterinary Pathologists and conducted federally and privately
funded research programs in immunogenetics, immunopathology and
transplantation biology since 1971. He has published more than 300 articles,
chapters and books in basic research and is recognized as a leading
investigator in the use of xenografts for human transplantation.
In addition to his scientific accomplishments Dr. Cramer has served as the
Director of Scientific Research in the Department of Surgery at Cedars-Sinai
Medical Center, and the Department of Cardiothoracic Surgery, University of
Southern California and member of many scientific advisory committees,
including the Comparative Medicine Review Committee, National Center for
Research Resources at the National Institutes of Health, and Secretary-
Treasurer of the International Xenotransplantation Association. Dr. Cramer
has served as Scientific Advisor to several biotechnology companies for the
evaluation and development of medical technologies including Exten Industries,
Ximerics, Inc., Apoimmune, Inc., Xenogenics, and Chief Scientific Officer,
Molecular Express, Inc. Dr. Cramer brings to QT5, Inc. a background
scientific expertise and business experience in the development of new medical
technologies for application in the treatment of a wide variety of medically
important diseases.
Dr. Leonard Makowka, MD. PhD.
Dr. Leonard Makowka leads the QT 5 advisory board as Senior Medical
Research Advisor. He is a distinguished clinical surgeon, transplantation
surgeon and medical researcher and is recognized as one of the World's leading
authorities in hepatic science (study relating to the liver). From 1995 to
1997, Dr. Makowka was the Executive Director of the Comprehensive Liver
Disease and Treatment Center and Director of the Liver Transplant Program at
St. Vincent's Medical Center in Los Angeles, CA. Between 1989 and 1995, Dr.
Makowka was the Chairman of the Department of Surgery and the Director of
Transplantation Services at Cedars-Sinai Medical Center in Los Angeles, CA. He
was also Professor of Surgery at the UCLA School of Medicine. Dr. Makowka
trained under Dr. Thomas Starzl, the pioneer of liver transplantation, and was
appointed Associated Professor in the Department of Surgery at the University
of Pittsburgh. In 1982, Dr. Makowka began his residency at the University of
Toronto, where in his final year he was appointed Chief Resident of Surgery.
Dr. Makowka has performed hundreds of hepatobiliary and liver transplant
procedures. Dr. Makowka received his M.D. degree from the University of
Toronto Medical School in 1977, and Master of Science and Doctorate of
Philosophy from the University of Toronto's Department of Pathology in 1979
and 1982. Dr. Makowka has published over 400 articles and chapters in both
clinical and basic scientific research and continues to lecture worldwide.
Dr. Howard Wilner, MD
Dr. Howard Wilner has participated on the QT 5 Advisory Board as Senior
Research Associate. He received his B.A. from Brooklyn College, and his M.D.
from New York University School of Medicine. After Post Graduate Training in
Internal Medicine, Nephrology, and Clinical Pharmacology and completion of
Military Service, Dr. Wilner entered the private practice of medicine. He is
Board Certified by the American Board of Internal Medicine as well as the
Subspecialty Board of Nephrology. Dr. Wilner has had a distinguished career in
medicine as both a Medical Executive and Practicing Physician. After serving
as the Clinical Chief of Medicine at Cedars-Sinai Medical Center, he was the
Executive Director of the Cedars-Sinai Comprehensive Cancer Center from 1988
through 1997. He remains on the Active Staff of the Hospital and in Private
Practice.
Dr. Marcus Laux, ND
Dr. Marcus Laux currently serves as a Medical Research Advisor in the
areas of Nutritional Science. He will also serve as Senior Associate Medical
Research spokesman for the NICOWater product line. He is a leading authority
on science-based natural medicines. Dr. Laux is a licensed naturopathic
physician with over a decade of private family practice. He received his
doctorate from National College of Naturopathic Medicine, Ptd, OR, where he
serves as a clinical professor. Dr. Laux is a leading authority on
science-based natural medicines, teaching continuing education seminars
internationally for medical doctors and pharmacists. He is former Chief
Science Officer for Nutrition for Life, Inc., and currently serves on several
scientific Advisory Boards including Phytopharmic Enzymatic Therapy, and
Unigen Pharmacia.
About QT 5, Inc.
QT 5, Inc. is a Delaware corporation formed in April 1999 as a
manufacturer, distributor and marketer of biomedical testing and Homeopathic
products. QT 5, Inc. currently manufactures and markets NICOWater, its
breakthrough Homeopathic Nicotinum (nicotine) product designed to relieve the
symptoms of tobacco cravings. QT 5, Inc. continues to do research and
development regarding future products for lifestyle enhancements. QT 5, Inc.
is headquartered in Westlake Village, California. For more information on the
Company please visit: http://www.qt5inc.com. NICOWater(TM) is a Homeopathic Drug
product that is sold under the FDA's Compliance Policy Guide Conditions Under
Which Homeopathic Drugs May Be Marketed.
This press release contains forward-looking statements that involve risks,
uncertainties and assumptions that, if they never materialize or prove
incorrect, could cause the results of QT 5, Inc. to differ materially from
those expressed or implied by such forward-looking statements. All statements
other than statements of historical fact are statements that could be deemed
forward-looking statements, including any projections of earnings, revenue, or
other financial items, any statements of the plans, strategies, and objectives
of management for future operations, any statements concerning proposed new
products, services or developments, any statements regarding future economic
conditions or performance, statements of belief and any statements of
assumptions underlying any of the foregoing. These statements are based on
expectations as of the date of this press release. Actual results may differ
materially from those projected because of a number of risks and
uncertainties, including those detailed from time to time in the reports filed
by QT 5, Inc. with the Securities and Exchange Commission. QT 5, Inc. assumes
no obligation and does not intend to update these forward-looking statements.
SOURCE QT 5, Inc.
 back to top
Related links:
http://www.qt5inc.com
CONTACT:
Steve Reder, President of QT 5, Inc.,
+1-818-338-1510, sreder@qt5inc.com; or Media - Peter Berk,
+1-310-274-1072, ext. 205, peter@crierpr.com, or J.P. Lincoln,
+1-310-274-1072, ext. 201, jp@crierpr.com, both of Crier
Communications, for QT 5, Inc.
|
